|
UK May Allow Early Access to Drugs Based on Strong Phase II, III Trials
Strong Phase III or even Phase II data may enable drugmakers to sell certain medicines for unmet needs in the UK before they are approved, thanks to a developing early access program.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives